Secondary analysis of a phase 3 RCT in 175 patients with obstructive HCM: at 24 weeks more aficamten than metoprolol patients were positive or complete responders across five disease-burden measures (78% vs 3%; P<0.001).
Secondary analysisn = 175 patients
Wang et al. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial